Tempus AI (TEM) Stock Overview
Operates as a healthcare technology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TEM Community Fair Values
Create NarrativeSee what 162 others think this stock is worth. Follow their fair value or set your own to get alerts.
Tempus AI, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$73.23 |
| 52 Week High | US$91.45 |
| 52 Week Low | US$31.36 |
| Beta | 0 |
| 1 Month Change | 18.11% |
| 3 Month Change | 34.54% |
| 1 Year Change | 23.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 81.94% |
Recent News & Updates
Tempus AI, Inc. (NASDAQ:TEM) Looks Just Right With A 28% Price Jump
Aug 15
Tempus AI Stock: Is It A Buy Following Guidance Raise?
Aug 12Recent updates
Tempus AI, Inc. (NASDAQ:TEM) Looks Just Right With A 28% Price Jump
Aug 15Tempus AI Stock: Is It A Buy Following Guidance Raise?
Aug 12
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities.The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Tempus: The AI Engine Powering Healthcare
Apr 20Is Tempus AI (NASDAQ:TEM) A Risky Investment?
Mar 25Tempus AI's Valuation Bakes In Strong Growth - A Hold For Now
Mar 25Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Mar 18Earnings Update: Here's Why Analysts Just Lifted Their Tempus AI, Inc. (NASDAQ:TEM) Price Target To US$64.11
Feb 27Tempus AI Earnings: A Promising Business, But There Are Risks
Feb 25Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
Feb 18Why Investors Shouldn't Be Surprised By Tempus AI, Inc.'s (NASDAQ:TEM) 82% Share Price Surge
Feb 11Tempus AI: In Vogue, But Better To Wait For Some Retracement
Feb 05Tempus AI: Don't Be Blindly Optimistic On Anything AI
Jan 28Tempus AI: Why I'm Avoiding This Stock In 2025
Jan 21The Price Is Right For Tempus AI, Inc (NASDAQ:TEM) Even After Diving 26%
Dec 18Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Dec 18Tempus AI: Why I'm Buying This AI Stock
Dec 08Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Nov 12Tempus: Attempting To Lead The AI Revolution In Healthcare
Oct 29Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Aug 21Tempus AI: Healthcare AI Play Faces Some Challenges From The Start
Jun 14Shareholder Returns
| TEM | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.07% | -0.5% | 1.9% |
| 1Y | 23.6% | -20.8% | 17.5% |
Return vs Industry: TEM exceeded the US Life Sciences industry which returned -20.8% over the past year.
Return vs Market: TEM exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| TEM volatility | |
|---|---|
| TEM Average Weekly Movement | 11.2% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TEM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TEM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2,400 | Eric Lefkofsky | www.tempus.com |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.
Tempus AI, Inc. Fundamentals Summary
| TEM fundamental statistics | |
|---|---|
| Market cap | US$13.26b |
| Earnings (TTM) | -US$199.73m |
| Revenue (TTM) | US$951.98m |
Is TEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEM income statement (TTM) | |
|---|---|
| Revenue | US$951.98m |
| Cost of Revenue | US$373.84m |
| Gross Profit | US$578.15m |
| Other Expenses | US$777.88m |
| Earnings | -US$199.73m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 60.73% |
| Net Profit Margin | -20.98% |
| Debt/Equity Ratio | 257.8% |
How did TEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/27 16:18 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempus AI, Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |
| Parth Talsania | Equisights |